Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Myeloproliferative neoplasms (essential thrombocythemia, ET; polycythemia vera, PV; myelofibrosis, MF) are monoclonal malignancies associated with genomic instability, dysregulated signaling pathways, and subsequent overproduction of inflammatory markers. Acknowledged for their debilitating symptom profiles, recent investigations have aimed to determine the identity of these markers, the upstream sources stimulating their development, their prevalence within the MPN population, and the role they play in symptom development. Creation of dedicated Patient Reported Outcome (PRO) tools, in combination with expanded access to cytokine analysis technology, has resulted in a surge of investigations evaluating the potential associations between symptoms and inflammation. Emerging data demonstrates clear relationships between individual MPN symptoms (fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms) and cytokines, particularly IL‐1, IL‐6, IL‐8, and TNF‐ α . Information is also compiling on the role symptoms paradoxically play in the development of cytokines, as in the case of fatigue‐driven sedentary lifestyles. In this paper, we explore the symptoms inherent to the MPN disorders and the potential role inflammation plays in their development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Self-citationInflammatory mediators in the elderly
Krabbe, K. S., Pedersen, M., & Bruunsgaard, H. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.01.009 · Cited by 928
Historical insights into cytokines
Dinarello, C. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737772 · Cited by 926 · cited 1×
“In general, cytokines (interleukins, interferons, and soluble growth factors; definitions in Table 2) are important regulators of cellular processes, particularly those involving immunomodulatory activities, cellular growth angiogenesis, and migration [18].”
BackgroundCytokines and their relationship to the symptoms and outcome of cancer
Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652
The Pain of Being Sick: Implications of Immune-to-Brain Communication for Understanding Pain
Watkins, L. R., & Maier, S. F. (2000) · Annual Review of Psychology · doi:10.1146/annurev.psych.51.1.29 · Cited by 388 · cited 1×
“In addition, inflammation and trauma have been shown to induce peripheral nerve cell release of inflammatory cytokines within the central nervous system via glial stimulation [45].”
BackgroundSparkman, N. L., Buchanan, J. B., Heyen, J. R. R., Chen, J., Beverly, J. L., & Johnson, R. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3376-06.2006 · Cited by 307
Low-dose endotoxemia and human neuropsychological functions
Krabbe, K. S., Reichenberg, A., Yirmiya, R., Smed, A., Pedersen, B. K., & Bruunsgaard, H. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.04.010 · Cited by 189
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma
Seymour, J. F., Talpaz, M., Cabanillas, F., Wetzler, M., & Kurzrock, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.575 · Cited by 164
Cited by
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
“In polycythemia vera (PV) and essential throbocythemia (ET), the JAK2 mutation can sustain a condition of chronic in fl ammation (1 – 3), explaining the associated constitutional symptoms, thrombosis, and premature atherosclerosis observed in patients with these disorders (4 – 6).”
The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis
Ratajczak, M. Z., Bujko, K., Cymer, M., Thapa, A., Adamiak, M., Ratajczak, J., Abdel-Latif, A. K., & Kucia, M. (2020) · Leukemia · doi:10.1038/s41375-020-0827-8 · Cited by 102
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
Schnöder, T. M., Eberhardt, J., Koehler, M., Bierhoff, H. B., Weinert, S., Pandey, A. D., Nimmagadda, S. C., Wolleschak, D., Jöhrens, K., Fischer, T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2354-1 · Cited by 13
Surapaneni, P., & Scherber, R. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00516-w · Cited by 10
Self-citation
Metadata
- Authors
- Geyer, H. L., Dueck, A. C., Scherber, R. M., & Mesa, R. A.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 284706-284706
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2097694060
- Cited by
- 125
- References
- 12
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.